CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Pharmaceutical
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all...
Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
$10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract...
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind...
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x higher.Noom stands...
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed...
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting
NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”),...
PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV
MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics...
PetMed Express, Inc. Announces Appointment of Robyn D’Elia as Chief Financial Officer
D’Elia Brings More than 25 Years of Strategic Finance and Retail Leadership Experience to PetMedsDELRAY BEACH, Fla., Sept. 12, 2024...
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...
Elevar Therapeutics Reports Advances in HCC and Other Oncology Clinical Programs for Rivoceranib Plus Camrelizumab at the European Society for Medical Oncology Congress 2024
FORT LEE, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today...
Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act
Scorpius Poised to Support Expanded U.S. Government-Backed Project Pipeline as U.S. Drugmakers Seek to Shift to Domestic Suppliers Amid Industry-Changing...
Biogen Board Appoints Two New Independent Directors
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and developmentCAMBRIDGE,...
Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories
CINCINNATI, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug...
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised...
Lifecore Biomedical Regains Compliance with Nasdaq Listing Requirements
CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated...